Incyte Stock: Is Wall Street Bullish or Bearish?
Incyte Corporation (INCY) is a biopharmaceutical company with a focus on the discovery, development, and commercialization of innovative therapeutics. Based in Wilmington, Delaware, the company operates in the United States, Europe, Canada, and Japan, marketing a range of oncology, immunology, and dermatology medicines such as JAKAFI, OPZELURA, and ICLUSIG.
INCY's shares have outperformed the broader market over the past 52 weeks, with a 42.1% increase versus the S&P 500's 20.1% gain. The stock has also gained 25% year-to-date, outpacing the S&P 500's 13.1% return. Analysts have a mixed view on the company's earnings, with 52.7% year-over-year decline expected for the fiscal year ending in December 2026.
Despite this, the consensus rating among the 26 analysts covering INCY is a Moderate Buy, based on 11 Strong Buy ratings and 15 Holds.
Written by urgent.news from Yahoo Finance's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.